Oncotarget: Cooperative tumorigenic effects of targeted deletions of tumor suppressors

Volume 11

,

Issue 28

of Oncotarget features ”


Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice


” by Xu et, al. which reported that the authors examined whether the TSGs Rb1, Trp53, Pten, and Men1 have cooperative effects in suppressing neuroendocrine tumors in mice.

By monitoring growth and examining the histopathology of the pituitary and pancreas in these mice, the authors demonstrated that pRB had the strongest cooperative function with PTEN in suppressing Pit NETs and had strong cooperative function with Menin and TRP53, respectively, in suppressing Pit NETs and Pan NETs. TRP53 had weak cooperative function with PTEN in suppressing pituitary lesions.

Collectively, the data indicated that pRB and PTEN pathways play significant roles in suppressing Pit NETs, while the Menin-mediated pathway plays a significant role in suppressing Pan NETs. Understanding the molecular mechanisms of these genes and pathways on NETs will help us understand the molecular mechanisms of neuroendocrine tumorigenesis and develop effective preclinical murine models for NET therapeutics to improve clinical outcomes in humans.

Dr. Eugenia Y. Xu from

Rutgers

and Princeton University as well as Dr. Daniel A. Notterman from

Princeton University

said, ”

Human pituitary neuroendocrine tumors (

PitNETs

) are the third most common intracranial neoplasms and represent approximately 10–25% of all primary intracranial tumors.

”

Additionally, in rare cases, RB1 has been found with epigenetic mutations in the promoter region in Pit NETs suggesting that inactivation of the RB pathway contributes to the development of Pit NETs. Compound mice with concomitant deletions of Men1 and Pten develop Pit NETs and Pan NETs and mice with p18–/– Pten+/– mutations develop Pit NETs, suggesting that PTEN plays a role in pituitary and pancreatic islet tumorigenesis.

However, Men1 deletion mice develop pars distalis prolactinomas and Rb1 deletion mice develop pars intermedia tumors of the pituitary, suggesting that the functions of Menin and pRB may not fully overlap.

Here they investigate the question of whether Men1 and Rb1 have cooperative tumorigenic effects on NETs using tissue-specific double homozygous deletions of Men1 and Rb1 in mice.

The Oncotarget authors report that the characterization of Pit NETs and Pan NETs with double homozygous deletions of TSGs and illustrate that pRB has the strongest cooperative function with PTEN in suppressing Pit NETs and has a strong cooperative function with Menin and TRP53, respectively, in suppressing Pit NETs and Pan NETs in mice.

“The Oncotarget authors report that the characterization of Pit NETs and Pan NETs with double homozygous deletions of TSGs and illustrate that pRB has the strongest cooperative function with PTEN in suppressing Pit NETs and has a strong cooperative function with Menin and TRP53, respectively, in suppressing Pit NETs and Pan NETs in mice.”

The Xu/Notterman Research Team concluded in their

Oncotarget


Research Paper

, ”

our data clearly demonstrate that TSGs Rb1, Pten, Men1, and Trp53 have distinct tissue specificity in neuroendocrine tumorigenesis in mouse and likely in man. The mouse models here and deletion of these TSGs in MIP-Cre mice will help further our understanding the molecular function of these TSGs and their pathways in PitNET and PanNET pathogenesis, which will help develop targeted novel therapeutic options in treating human patients.

”

Sign up for free Altmetric alerts about this article

DOI

–

https:/

/

doi.

org/

10.

18632/

oncotarget.

27660

Full text

–

https:/

/

www.

oncotarget.

com/

article/

27660/

text/

Correspondence to

– Eugenia Y. Xu –

exu@princeton.edu

and Daniel A. Notterman –

dan1@princeton.edu

Keywords

–


neuroendocrine tumors

,

RB1

,

Trp53

,

PTEN

,

Men1

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit

https:/

/

www.

oncotarget.

com

or connect with:

SoundCloud –


https:/

/

soundcloud.

com/

oncotarget



Facebook –


https:/

/

www.

facebook.

com/

Oncotarget/

Twitter –


https:/

/

twitter.

com/

oncotarget



LinkedIn –


https:/

/

www.

linkedin.

com/

company/

oncotarget



Pinterest –


https:/

/

www.

pinterest.

com/

oncotarget/

Reddit –


https:/

/

www.

reddit.

com/

user/

Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit

http://www.

ImpactJournals.

com

or connect with

@ImpactJrnls